Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory

Nature Neuroscience

Volumn 17, Issue 7, 2014, Pages 971-980

  Hait, Nitai C ^a,b   Wise, Laura E ^a   Allegood, Jeremy C ^a,b   O'Brien, Megan ^a   Avni, Dorit ^a,b   Reeves, Thomas M ^a   Knapp, Pamela E ^a   Lu, Junyan ^c   Luo, Cheng ^c   Miles, Michael F ^a   Milstien, Sheldon ^a,b   Lichtman, Aron H ^a   Spiegel, Sarah ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FINGOLIMOD; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEAR RECEPTOR RELATED FACTOR 1; PROTEIN C FOS; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 2; VASCULOTROPIN D; HISTONE H2B; HISTONE H3; HISTONE H4; VORINOSTAT;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CELL NUCLEUS; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOPLASM; DRUG PROTEIN BINDING; EMBRYO; ENZYME INHIBITION; FEAR; GENE EXPRESSION; HIPPOCAMPUS; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; LEARNING; LONG TERM POTENTIATION; MALE; MEMORY; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY; UPREGULATION; ENZYME PHOSPHORYLATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN CELL; SCID MOUSE;

ANIMALS; BLOTTING, WESTERN; BRAIN; EXPLORATORY BEHAVIOR; EXTINCTION, PSYCHOLOGICAL; FEAR; GENE EXPRESSION; HIPPOCAMPUS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; ISOENZYMES; LEARNING DISORDERS; LYSOPHOSPHOLIPIDS; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MICE, SCID; MODELS, MOLECULAR; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROPYLENE GLYCOLS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPHINGOSINE;

EID: 84903270821     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3728     Document Type: Article

References (58)

1. Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897 (2010).
2. Cyster, J.G. & Schwab, S.R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30, 69-94 (2012).
3. Foster, C.A. et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 323, 469-475 (2007).
4. Hla, T. & Brinkmann, V. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology 76, S3-S8 (2011).
5. Hait, N.C. et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325, 1254-1257 (2009).
6. Alvarez, S.E. et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465, 1084-1088 (2010).
7. Igarashi, N. et al. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem. 278, 46832-46839 (2003).
8. Kazantsev, A.G. & Thompson, L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7, 854-868 (2008).
9. Fischer, A., Sananbenesi, F., Mungenast, A. & Tsai, L.H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 31, 605-617 (2010).
10. Bressi, J.C. et al. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg. Med. Chem. Lett. 20, 3142-3145 (2010).
11. Finnin, M.S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188-193 (1999).
12. Choi, J.W. et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. USA 108, 751-756 (2011).
13. Mandala, S. et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346-349 (2002).
14. Allende, M.L. et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 279, 52487-52492 (2004).
15. Briard, E. et al. BZM055, an iodinated radiotracer candidate for PET and SPECT imaging of myelin and FTY720 brain distribution. Chem Med Chem 6, 667-677 (2011).
16. Bredy, T.W. et al. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn. Mem. 14, 268-276 (2007).
17. Lattal, K.M., Barrett, R.M. & Wood, M.A. Systemic or intrahippocampal delivery of histone deacetylase inhibitors facilitates fear extinction. Behav. Neurosci. 121, 1125-1131 (2007).
18. Bredy, T.W. & Barad, M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn. Mem. 15, 39-45 (2008).
19. Vecsey, C.G. et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci. 27, 6128-6140 (2007).
20. Stefanko, D.P., Barrett, R.M., Ly, A.R., Reolon, G.K. & Wood, M.A. Modulation of long-term memory for object recognition via HDAC inhibition. Proc. Natl. Acad. Sci. USA 106, 9447-9452 (2009).
21. Kipnis, J., Cohen, H., Cardon, M., Ziv, Y. & Schwartz, M. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl. Acad. Sci. USA 101, 8180-8185 (2004).
22. Brynskikh, A., Warren, T., Zhu, J. & Kipnis, J. Adaptive immunity affects learning behavior in mice. Brain Behav. Immun. 22, 861-869 (2008).
23. Gräff, J. et al. Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 156, 261-276 (2014).
24. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010).
25. Yirmiya, R. & Goshen, I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25, 181-213 (2011).
26. Guan, J.S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55-60 (2009).
27. Peleg, S. et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328, 753-756 (2010).
28. Derecki, N.C. et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med. 207, 1067-1080 (2010).
29. Mauceri, D., Freitag, H.E., Oliveira, A.M., Bengtson, C.P. & Bading, H. Nuclear calcium-VEGFD signaling controls maintenance of dendrite arborization necessary for memory formation. Neuron 71, 117-130 (2011).
30. Stefansson, H. et al. Common variants conferring risk of schizophrenia. Nature 460, 744-747 (2009).
31. Brzózka, M.M., Radyushkin, K., Wichert, S.P., Ehrenreich, H. & Rossner, M.J. Cognitive and sensorimotor gating impairments in transgenic mice overexpressing the schizophrenia susceptibility gene Tcf4 in the brain. Biol. Psychiatry 68, 33-40 (2010).
32. McQuown, S.C. et al. HDAC3 is a critical negative regulator of long-term memory formation. J. Neurosci. 31, 764-774 (2011).
33. Orlandini, M., Marconcini, L., Ferruzzi, R. & Oliviero, S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl. Acad. Sci. USA 93, 11675-11680 (1996).
34. Patterson, S.L. et al. Some forms of cAMP-mediated long-lasting potentiation are associated with release of BDNF and nuclear translocation of phospho-MAP kinase. Neuron 32, 123-140 (2001).
35. Alarcón, J.M. et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/? mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42, 947-959 (2004).
36. Levenson, J.M. et al. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279, 40545-40559 (2004).
37. Liu, H. et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem. 275, 19513-19520 (2000).
38. Blondeau, N. et al. Distribution of sphingosine kinase activity and mRNA in rodent brain. J. Neurochem. 103, 509-517 (2007).
39. Liang, J. et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23, 107-120 (2013).
40. Fujita, Y. et al. Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene. J. Psychiatr. Res. 46, 635-643 (2012).
41. Day, J.J. & Sweatt, J.D. Epigenetic mechanisms in cognition. Neuron 70, 813-829 (2011).
42. Zovkic, I.B. & Sweatt, J.D. Epigenetic mechanisms in learned fear: implications for PTSD. Neuropsychopharmacology 38, 77-93 (2013).
43. Deogracias, R. et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. USA 109, 14230-14235 (2012).
44. Peters, J., Dieppa-Perea, L.M., Melendez, L.M. & Quirk, G.J. Induction of fear extinction with hippocampal-infralimbic BDNF. Science 328, 1288-1290 (2010).
45. Soliman, F. et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 327, 863-866 (2010).
46. Hawk, J.D. et al. NR4A nuclear receptors support memory enhancement by histone deacetylase inhibitors. J. Clin. Invest. 122, 3593-3602 (2012).
47. Lee, Y.S. & Silva, A.J. The molecular and cellular biology of enhanced cognition. Nat. Rev. Neurosci. 10, 126-140 (2009).
48. Maren, S. Seeking a spotless mind: extinction, deconsolidation, and erasure of fear memory. Neuron 70, 830-845 (2011).
49. Tronson, N.C., Corcoran, K.A., Jovasevic, V. & Radulovic, J. Fear conditioning and extinction: emotional states encoded by distinct signaling pathways. Trends Neurosci. 35, 145-155 (2012).
50. Beaudoin, G.M. III et al. Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat. Protoc. 7, 1741-1754 (2012).
51. Fitting, S. et al. Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol. Psychiatry 73, 443-453 (2013).
52. Plendl, W. & Wotjak, C.T. Dissociation of within- and between-session extinction of conditioned fear. J. Neurosci. 30, 4990-4998 (2010).
53. Varvel, S.A., Hamm, R.J., Martin, B.R. & Lichtman, A.H. Differential effects of delta 9-THC on spatial reference and working memory in mice. Psychopharmacology (Berl.) 157, 142-150 (2001).
54. Lazenka, M.F., Selley, D.E. & Sim-Selley, L.J. DeltaFosB induction correlates inversely with CB receptor desensitization in a brain region-dependent manner following repeated delta-THC administration. Neuropharmacology 77, 224-233 (2014).
55. Kerns, R.T. et al. Ethanol-responsive brain region expression networks: implications for behavioral responses to acute ethanol in DBA/2J versus C57BL/6J mice. J. Neurosci. 25, 2255-2266 (2005).
56. Zhang, L., Wang, L., Ravindranathan, A. & Miles, M.F. A new algorithm for analysis of oligonucleotide arrays: application to expression profiling in mouse brain regions. J. Mol. Biol. 317, 225-235 (2002).
57. Chen, J., Bardes, E.E., Aronow, B.J. & Jegga, A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305-W311 (2009).
58. Baker, E.J., Jay, J.J., Bubier, J.A., Langston, M.A. & Chesler, E.J. GeneWeaver: a web-based system for integrative functional genomics. Nucleic Acids Res. 40, D1067-D1076 (2012).